The phase Ib/II SCORES trial for advanced solid tumors, including R/M HNSCC, showed that durvalumab in combination with AZD9150 (35 patients in this arm with 15 patients receiving prior PD-L1 treatment) achieved an objective RR of 25% in 20 CPI-naive patients, with a disease control rate (DCR) of 45% at 12 weeks and 30% patients still on treatment at 25 weeks. This evidence concerns the gene CD274 and head and neck squamous cell carcinoma.